Boston Scientific

TriMed Staff | October 08, 2008 | Cardiovascular Business | Patient Care

Boston Scientific (Booth 814) is highlighting various lectures, presentations and analyses of the recently released results of the SYNTAX trial.

The SYNTAX trial aims to explore the interface between treatment with CABG and PCI in patients with three-vessel and left main stem disease, comparing CABG using contemporary techniques and PCI using Boston Scientific’s Taxus drug eluting stents.

The majority of the lectures and presentations will take place on Tuesday, Oct, 14, when from 2:00-6:00, an entire session will be dedicated to the “Revascularization for Left Main and Triple Vessel Disease: Focus on SYNTAX” in room 147AB.

TriMed Staff

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business

Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Related Content

Around the web